The Premier healthcare alliance today announced new agreements for radiopharmaceutical distribution and manufacturers have been awarded to Cardinal Health, Inc. of Dublin, Ohio; Lantheus Medical Imaging of North Billerica, Mass., a small business enterprise; Mallinckrodt LLC, a Covidien company, of Hazelwood, Mo.; and Triad Isotopes of Orlando, Fla.
Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that one-year results on the use of its EverFlex™ stent for superficial femoral artery stenting were presented here during the International Symposium on Endovascular Therapy (ISET) Conference.
AMERICAN SHARED HOSPITAL SERVICES (NYSE AMEX:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that it has entered into a contract to supply a Gamma Knife® PerfexionTM system to Sacred Heart Health System in Pensacola, Florida. Pending regulatory approval, patient treatments on this Perfexion system are expected to begin this fall. AMS, the largest owner of Gamma Knife Perfexion systems worldwide, is placing its twelfth Perfexion system in the United States at Sacred Heart.
Final Results from DEFINITIVE Ca++ Clinical Study Presented at ISET 2012
COMPANY TO DISCUSS THERMOSTEM™ PROGRAM ON METABOLIC DISORDERS AND OBESITY
LTS Nutraceuticals, Inc. (the “Company”) (OTCBB: LTSN), a developer and manufacturer of nutritional and personal care products, today announced that a clinical study was done on BioCalth® product that confirmed BioCalth’s effectiveness in repairing bone deterioration. The study was conducted by Dr. Jing Liang MD PhD, Associate Professor of Molecular & Medical Pharmacology at the David Geffen School of Medicine, UCLA. Dr. Liang has over 20 years of experience in pharmaceutical research and development.
Rainbow Coral Corp. (OTCBB:RBCC) begins the search today for a capable investment banking firm to assist in procuring capital for the acquisition of Nano3D Biosciences (n3D) and other target companies.
Rising demand for cutting-edge stem cell therapies for diabetes could blossom into a booming market for products commercialized by Rainbow Coral Corp. (OTCBB:RBCC).
Company announces the appointment of four new executives and two promotions
Company to Present at Vaccine Forum Washington 2012
CytoDyn Inc. (the "Company") (OTC QB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, and other antibody applications, announced today that Ismail Abdul Fattah will serve as the Company's Senior Advisor of Business Development for the Middle East. Mr. Fattah will continue to serve in his role with AM Financials s.a.l, in Beirut, Lebanon. As part of the Company's evolution and international business development activities, Mr. Fattah will work in conjunction with Dr. Nadar Pourhassan, the Company's Managing Director of Business Development, to expand the Company's business development activities in the Middle East.
Fibromuscular Dysplasia Most Likely To Strike Women, Suggests Registry
Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that nonclinical data on the immunologic mechanism of action of PV-10 will be presented at the Society of Surgical Oncology Annual Meeting, March 21-24, 2012, at the Orlando World Center Marriott in Orlando, Florida. The data, by Dr. Paul Toomey and colleagues of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, will be presented in the melanoma poster session, time and location to be announced at a later date.
Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that Craig Dees, Ph.D., CEO, will present at BOCEMb: Noble Financial Capital Markets' Eighth Annual Equity Conference on January 18, 2012 at 1:00 PM EST. The conference will be held in Hollywood, Florida at the Hard Rock Hotel.
Data presented at the 6th Annual Human Amyloid Imaging (HAI) meeting in Miami suggest that the investigational imaging agent [18F] Flutemetamol could add value to current diagnostic tools used by physicians to evaluate neurodegenerative conditions like Alzheimer’s Disease (AD). [18F]Flutemetamol is a GE Healthcare PET imaging agent in phase III development for the detection of beta amyloid.
/PRNewswire/ -- NeutronicEar, the leader in Personal Sound Amplification Products (PSAP) today announced direct-to-consumer sales and reduced pricing on their newly re-designed website www.neutronicear.com . The website will feature all NeutronicEar products as well as discounted pricing on consumable accessories including special member pricing on batteries.
ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (OTCBB: IMUC.OB), an emerging biotechnology company focused on developing novel-immune-based therapies, today announced that its President and CEO, Manish Singh Ph.D., will present at the Noble Financial Capital Markets Eighth Annual Equity Conference, being held at the Hard Rock Hotel in Hollywood, Florida from January 16-18, 2012.
When Rainbow Coral Corp. (OTCBB:RBCC) moved its biosciences division to Houston, Texas, it tapped into an economic hot bed. According to local economists, Houston’s biotechnology sector outpaced every other sector of the city’s economy last year.
Although using angioplasty to treat multiple sclerosis (MS) is highly controversial, sufferers often insist it helps – in some cases dramatically, such as allowing them to walk without a cane. Patients with less severe MS also reported additional quality of life improvements, such as being able to talk more clearly, after having treatment to open blocked blood vessels in the chest and neck, according to research being presented at the 24th annual International Symposium on Endovascular Therapy (ISET).
AxoGen, Inc. (OTCBB: AXGN), an emerging regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today reported the publication of peer-reviewed clinical research conducted at twelve leading US surgical sites and led by the Buncke Clinic in San Francisco. The study, which is the first, multi-center clinical trial on processed nerve allografts, found that the Avance® Nerve Graft achieved meaningful recovery in 87 percent of patients with peripheral nerve injuries. A summary of the findings were published in the January 2012 issue of Microsurgery.1
RSS|
My Yahoo|
Newsletters|
Mobile|
Alerts|
Twitter
Terms of Service| Privacy Policy| About our ads| Copyright| About The Miami Herald| About the McClatchy Company| Corrections| Contact Us| Advertise| Work for Us
Partners: El Nuevo Herald| Newspaper in Education| WLRN | Miami Herald News| CBS4 WFOR-TV| More
Copyright 2012 Miami Herald Media Co. All rights reserved
Previous